Ag85B-MPT70-Rv2660c fusion protein (H107) (H107)

The Ag85B-MPT70-Rv2660c fusion protein, commonly known as H107, is a recombinant multi-stage vaccine candidate developed to provide protection against Mycobacterium tuberculosis (Mtb) [1]. It is engineered by fusing three key Mtb antigens: Antigen 85B (Ag85B), MPT70, and Rv2660c [1, 2]. Ag85B is a major secretory protein involved in cell wall synthesis, while MPT70 is a secreted protein highly expressed during the early stages of infection [1]. Rv2660c is a latency-associated protein that is upregulated during bacterial starvation and dormant phases [1, 3]. By combining these antigens, the fusion protein aims to elicit a broad immune response that targets the bacteria during both active replication and latent persistence [2]. The primary biological function of this target in a clinical context is to stimulate Th1-type cellular immunity, leading to the production of protective cytokines like interferon-gamma and TNF-alpha [1]. In vaccine formulations, it is typically combined with an adjuvant such as IC31 to enhance its immunogenic profile [2]. This target is primarily investigated for its role in preventing tuberculosis infection and potentially as a therapeutic vaccine to prevent reactivation in latent carriers [3].

Other names

H107Ag85B-Rv2660c-MPT70Recombinant fusion protein Ag85B-MPT70-Rv2660c

Induction of Th1-type cellular immune response against multiple stages of Mycobacterium tuberculosis infection